| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
G1 Therapeutics Inc (NASDAQ: GTHX)
GTHX Technical Analysis
5
| As on 9th Jun 2023 GTHX STOCK Price closed @ 2.76 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 9.14 & Strong Sell for SHORT-TERM with Stoploss of 10.01 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GTHXSTOCK Price
| Open | 2.85 | Change | Price | % |
| High | 2.88 | 1 Day | -0.07 | -2.47 |
| Low | 2.75 | 1 Week | 0.14 | 5.34 |
| Close | 2.76 | 1 Month | 0.30 | 12.20 |
| Volume | 539224 | 1 Year | -7.81 | -73.89 |
| 52 Week High 16.99 | 52 Week Low 2.46 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| GTHX Daily Charts |
GTHX Intraday Charts |
Whats New @ Bazaartrend |
GTHX Free Analysis |
|
|
GTHX Important Levels Intraday
| RESISTANCE | 3.01 |
| RESISTANCE | 2.93 |
| RESISTANCE | 2.88 |
| RESISTANCE | 2.83 |
| SUPPORT | 2.69 |
| SUPPORT | 2.64 |
| SUPPORT | 2.59 |
| SUPPORT | 2.51 |
GTHX Forecast May 2024
| 4th UP Forecast | 9.1 |
| 3rd UP Forecast | 7.07 |
| 2nd UP Forecast | 5.81 |
| 1st UP Forecast | 4.55 |
| 1st DOWN Forecast | 0.97 |
| 2nd DOWN Forecast | -0.29 |
| 3rd DOWN Forecast | -1.55 |
| 4th DOWN Forecast | -3.58 |
GTHX Weekly Forecast
| 4th UP Forecast | 5.21 |
| 3rd UP Forecast | 4.42 |
| 2nd UP Forecast | 3.94 |
| 1st UP Forecast | 3.45 |
| 1st DOWN Forecast | 2.07 |
| 2nd DOWN Forecast | 1.58 |
| 3rd DOWN Forecast | 1.10 |
| 4th DOWN Forecast | 0.31 |
GTHX Forecast2024
| 4th UP Forecast | 31.88 |
| 3rd UP Forecast | 22.54 |
| 2nd UP Forecast | 16.77 |
| 1st UP Forecast | 10.99 |
| 1st DOWN Forecast | -5.47 |
| 2nd DOWN Forecast | -11.25 |
| 3rd DOWN Forecast | -17.02 |
| 4th DOWN Forecast | -26.36 |
G1 Therapeutics Inc ( NASDAQ USA Symbol : GTHX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GTHX Business Profile
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina. Address: 700 Park Offices Drive, Research Triangle Park, NC, United States, 27709
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service